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response to bowel cleansing products, and to assess the psycho-
metric and scaling properties of the new measure. METHODS:
Instrument content was derived via qualitative interviews con-
ducted with patients in the UK. Face and content validity were
assessed via patient cognitive-debrieﬁng interviews. Psychometric
and scaling properties were assessed via a survey. Patients com-
pleted the BOCLIR and demographic questions prior to colonos-
copy. Item response theory (Rasch analysis) was employed for
item reduction and unidimensionality. Internal consistency and
construct validity (association of BOCLIR scores with known
factors) were also assessed. RESULTS: Qualitative interviews
(n = 40/58%M) highlighted key areas of patient concern as;
satisfaction with the bowel cleanser, impairments (adverse
events) and activity limitations. A draft questionnaire was con-
structed comprising three scales addressing these areas.
Cognitive-debrieﬁng interviews (n = 19/63%M) demonstrated
BOCLIR’s acceptability, relevance, clarity and ease of comple-
tion. Survey sample: n = 166/52%M, mean age 54.3/SD 15.2
years. Application of Rasch analysis removed misﬁtting or redun-
dant items. Final scales ﬁt the Rasch model as indicated by
non-signiﬁcant c2 p-values (p > 0.13 for all scales), conﬁrming
unidimensionality. Cronbach’s alpha coefﬁcients were high indi-
cating good internal consistency; Satisfaction 0.84, Impairments
0.77, Activities 0.94. There were signiﬁcant differences in
BOCLIR scores between patients based on their willingness to
use the product in future and on ease of drinking the full prepa-
ration (p < 0.01). For Impairments and Activities scales signiﬁ-
cant differences were also observed between patients dependent
on how well they felt and satisfaction with the preparation
(p < 0.001). CONCLUSIONS: The BOCLIR is a new question-
naire comprised of unidimensional scales (satisfaction, impair-
ments and activities) with good psychometric and scaling
properties. The BOCLIR will allow accurate assessment of
patients’ response to bowel cleansing preparations.
PGI23
QUALITY OF LIFE (HEALTH-RELATED UTILITY) IN ADULTS
WITH ULCERATIVE COLITIS IN REMISSIONVS. MILD/
MODERATE AND SEVERE RELAPSE: FINDINGS FROMTHE
PODIUM STUDY
Poole CD1, Nielsen SK2, Currie CJ3, Connolly M4
1Pharmatelligence, Cardiff, South Glamorgan, UK, 2Ferring International
Center, Saint-Prex, Switzerland, 3Cardiff University, Cardiff, UK, 4Global
Market Access Solutions, St Prex, Switzerland
OBJECTIVES: Ulcerative colitis (UC) is a chronic inﬂammatory
condition characterised by remission and relapse. Although UC
disease severity is a strong predictor of quality of life, the impact
of disease relapse on health-related utility compared to remission
has never been characterised. It has been found that at 12
months, 71% of subjects remained in remission on once daily
mesalazine (Pentasa; 1x2g) vs. 59% in twice-daily mesalazine
(2x1g), p = 0.024, using Kaplan Meier analysis (Dignass, 2007).
METHODS: The purpose of this study was to examine quality of
life by estimating changes in health-related utility associated with
transition from a remitting to relapsing states in adults with
established UC. Data were analysed from the Phase-3 PODIUM
trial (Pentasa Once Daily In Ulcerative colitis for Maintenance of
remission). Patients were classiﬁed into the following disease
states at baseline and at 12 months based on their UC disease
activity index (UC-DAI): remission, 2; mild/moderate relapse,
3–8; and severe relapse, 9. Health utility was estimated by
Monte Carlo bootstrap simulation using a response mapping
algorithm to predict EQ-5D domain response from UC-DAI item
scores and applying the UK tariff for preference based utility.
RESULTS: Evaluable data were available for 359 patients, 53%
of whom were male, with a mean age at screening of 48 years (SD
 15). At baseline, all patients were in remission and had a mean
EQ-5D index of 0.945 (SD  0.023). At 12 months, 73.8% of
patients remained in remission, 22.6% were in mild/moderate
relapse, and 3.6% were in severe relapse. There were no baseline
differences between patients relapsing or remitting at 12 months;
however, signiﬁcant differences in utility emerged at 12 months.
For patients in remission at 12-months, their mean utility was
0.940 units (95%CI 0.937–0.943), whilst for mild/moderate
relapsing cases their mean utility was 0.775 units (95%CI 0.751–
0.800) and 0.660 units (95%CI 0.595–0.725) for those in severe
relapse (p < 0.001). CONCLUSIONS: Patients with relapsing
UC showed considerable decrease in health-related utility con-
sistent with disease severity. Patients in mild/moderate relapse
had health-related utility comparable to those with cardiac dys-
rhythmia (0.774) or gout (0.771), whilst severe relapsing patients
had similar disutility to those with emphysema (0.663) or renal
failure (0.651). Maintenance treatments that prolong the UC
remission phase are likely to have substantial beneﬁts on health
related utility.
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OBJECTIVES: Additional validity evidences have been gathered
to support the adequacy of the Gastrointestinal Short Form
Questionnaire (GSFQ) adapted to (Iberian) Spanish culture. The
GSFQ questionnaire is a speciﬁc HRQoL instrument which
measures the impact of Gastroesophageal Reﬂux Disease (GERD)
symptoms. If the GSFQ is to be a valid measure of patient’s
HRQoL it should be possible to stratify and discriminate patients
using the questionnaire score as criteria. METHODS: A national
representative sample of GERD patients was selected, stratiﬁed by
gender, age (<45, 45 years) and GERD severity (0-I, II-IV
Savary-Miller score) for validation purposes. Age, gender, BMI,
GERD diagnose, GERD severity, associated comorbidities and
risk factors were recorded. GSFQ, EuroQol, and the correspond-
ing Visual Analogue Scale (VAS) were answered by patients. A
semantic reduction of reported comorbidities was carried out to
attain a ﬁnal clustering of pathologies. Using the GERD score as a
continuous dependent criteria, several segmentation models were
studied with different sets of predictive variables. CHAID and
CR&T tree growing algorithms were used. Obtained stratum
proﬁles were further explored on non-signiﬁcant variables in the
search of multicolinearity and surrogates. RESULTS: A total of
3997 patients were recruited by 490 clinicians. Mean age was 49
(14.4) years and 48.4% were women. Reported comorbidities
were clustered in 6 antecedents and 15 concomitant pathologies.
Although hypertension was the most frequent comorbidity
(15.8%) only a small relation with other pathologies was found
(mainly with Diabetes, Dyslipemia, Osteoarthritis and Hypercho-
lesterolemia). The best stratiﬁcation predictor of mean GSFQ
score was the EQ-5D utility score. GERD severity, EQ-5D VAS
QoL, alcohol consumption, tabaquism, age, carbonic beverage
consumption depression and Ostheoartritis were also signiﬁcant
predictors at different tree levels. CONCLUSIONS: The Spanish
version of the GSFQ is sensitive to differences between patients
with respect to HRQoL, comorbidities and several risk factors.
Surprisingly, some risk factorswhich had no simple direct effect on
GSFQ scores were signiﬁcant in combination with other segmen-
tation criteria at lower tree levels.
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